Novartis cuts manufacturing jobs, closes North Carolina plant ahead of Sandoz spinoff

By the end of 2023, Novartis plans to shutter its Sandoz oral solid dosage plant in Wilson, North Carolina, where the company’s soon-to-be-spun-off generics division makes products such as tablets and capsules for Canada and the U.S. The site’s roughly 246 employees have already been alerted to the closure, a Novartis spokesperson said over email.